Literature DB >> 33543462

In Vitro Assays for Nanoparticle-Cancer Cell Interaction Studies.

Tomás Bauleth-Ramos1,2,3,4, Bruno Sarmento5,6,7.   

Abstract

Nanotechnology is a rapid-growing field with an extreme potential to revolutionize cancer treatments. However, despite the rapid advances, the clinical translation is still scarce. One of the main hurdles contributing for this setback is the lack of reliable in vitro models for preclinical testing capable of predicting the outcomes in an in vivo setting. In fact, the use of 2D monolayers, considered the gold-standard in vitro technique, leads to the creation of misleading data that might not be completely observed in in vivo or clinical setting. Thus, there is the need to use more complex models capable of better mimicking the tumor microenvironment. For that purpose, the development and use of multicellular tumor spheroids, three-dimensional (3D) cell cultures which recapitulate numerous aspects of the tumors, represents an advantageous approach to test the developed anticancer therapies. In this chapter, we identify and discuss the advantages of the use of these 3D cellular models compared to the 2D models and how they can be utilized to study nanoparticle-cancer cell interaction in a more reliable way to predict the treatment outcome in vivo.

Entities:  

Keywords:  3D; Cancer; Distribution; Efficacy; Extracellular matrix; High throughput screening; In Vitro; Nanoparticles; Nanotechnology; Spheroids; Toxicity; Tumor microenvironment

Year:  2021        PMID: 33543462     DOI: 10.1007/978-3-030-58174-9_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  88 in total

Review 1.  3D cell culture systems modeling tumor growth determinants in cancer target discovery.

Authors:  Claudio R Thoma; Miriam Zimmermann; Irina Agarkova; Jens M Kelm; Wilhelm Krek
Journal:  Adv Drug Deliv Rev       Date:  2014-03-15       Impact factor: 15.470

2.  Smart cancer nanomedicine.

Authors:  Roy van der Meel; Einar Sulheim; Yang Shi; Fabian Kiessling; Willem J M Mulder; Twan Lammers
Journal:  Nat Nanotechnol       Date:  2019-11-06       Impact factor: 39.213

3.  Learning/teaching styles: cognitive mapping.

Authors:  L L Rosenbloom
Journal:  J N Y State Nurses Assoc       Date:  1980-03

Review 4.  Cancer nanomedicine: progress, challenges and opportunities.

Authors:  Jinjun Shi; Philip W Kantoff; Richard Wooster; Omid C Farokhzad
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

Review 5.  Nanoparticle and targeted systems for cancer therapy.

Authors:  Lisa Brannon-Peppas; James O Blanchette
Journal:  Adv Drug Deliv Rev       Date:  2004-09-22       Impact factor: 15.470

Review 6.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Authors:  Jennifer I Hare; Twan Lammers; Marianne B Ashford; Sanyogitta Puri; Gert Storm; Simon T Barry
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

Review 7.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

Review 8.  Cell spheroids: the new frontiers in in vitro models for cancer drug validation.

Authors:  Maria Chatzinikolaidou
Journal:  Drug Discov Today       Date:  2016-06-29       Impact factor: 7.851

Review 9.  Lessons from patient-derived xenografts for better in vitro modeling of human cancer.

Authors:  Stephen Yiu Chuen Choi; Dong Lin; Peter W Gout; Colin C Collins; Yong Xu; Yuzhuo Wang
Journal:  Adv Drug Deliv Rev       Date:  2014-10-13       Impact factor: 15.470

10.  The difficulties in cancer treatment.

Authors:  Sajib Chakraborty; Taibur Rahman
Journal:  Ecancermedicalscience       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.